Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Health Canada.
2025
2024
2023
2022
2021
2020
2019
2018
2017
Home
/
Latest News
/
2025
2025
Date
Title
2025-11-11
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Health Canada.
>
2025-11-10
The Company’s 2025Q3 consolidated financial statements have been approved by the Board of Directors
>
2025-10-27
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Argentina National Administration of Drugs, Foods, and Medical Devices (ANMAT).
>
2025-10-03
The medical device registration application of Bonvadis for all indications in wounds has been accepted by ThaiFDA.
>
2025-10-03
The medical device registration application of Bonvadis for all indications of wounds has been accepted by COFEPRIS in Mexico.
>
2025-09-17
A Thailand patent on the Anti-CεmX (FB825) antibody was granted
>
2025-08-29
A U.S. patent titled ”METHODS FOR PREPARATION OF PLECTRANTHUS AMBOINICUS EXTRACTS” has been granted.
>
2025-08-28
Oneness has decided to discontinue the development of OB318 based on considerations of research and development efficiency.
>
2025-08-19
News-Promoting “Yellow Carbon”: Oneness Biotech and National Chung Hsing University Reveal Breakthroughs in Organic Farming Carbon Sequestration
>
2025-08-08
The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors
>
2025-07-28
The medical device registration application of Bonvadis for all indications in wounds has been accepted by Morocco AMMPS.
>
2025-07-18
Fespixon, the new drug in treatment of diabetic foot ulcers has been approved by Indonesia BPOM and the drug license has been granted.rt-hit of stock trading in the security market.
>
2025-06-10
Today, Bonvadis is 510(k) cleared by the U.S. FDA for full-thickness chronic wounds, marking a significant milestone in international commercialization.
>
2025-06-10
Mechanism of ON101 cream for prevention and treatment of radiation dermatitis has been published in the SCI journal, Life Sciences
>
2025-05-22
The cost-saving benefits of Fespixon in Singapore’s healthcare setting has been published in the SCI journal Diabetes, Obesity and Metabolism.
>
1
2
3
Next »
